Furthermore, pharmacologically targeting the myristoylation of the FRS2 scaffold protein whose role in prostate cancer has been elaborated in Chapter 3.1, inhibits FGF/FGFR-mediated oncogenic signaling and consequently the prostate cancer progression [419]. The gene discussed is FRS2; the disease is prostate carcinoma.